News
March 2, 2021
Mitokinin, Inc., Enters into Purchase Right Agreement with AbbVie
Agreement focused on advancing Mitokinin’s PINK1 activator program for the potential treatment of Parkinson’s disease
February 7, 2020
Mitokinin CSO Nicholas Hertz, PhD, to present at February 2020 Keystone Symposium
Mitokinin CSO Nicholas Hertz, PhD, will be presenting an overview of the Company’s PINK1 program…
January 12, 2020
Mitokinin Presents at 3rd Annual Sachs Neuroscience Investor Forum
Mitokinin joined 300 delegates from the biopharma and venture industries and 35 peer companies at the 3rd annual Sachs Neuroscience Investor Forum…
October 15, 2019
Mitokinin announces new award from the Michael J. Fox Foundation
Mitokinin today announced that The Michael J. Fox Foundation has awarded the Company a $300,000 grant to advance…
October 1, 2019
Mitokinin appoints Michael D. Taylor, PhD, Executive Chairman
Mitokinin, a late-preclinical stage biotechnology company developing PINK1-targeted therapies for…
June 15, 2019
Mitokinin to present at the Keystone Symposium on Neurodegeneration
Mitokinin, a late-preclinical stage biotechnology company developing PINK1-targeted therapies for…